Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Hepatic Impairment

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

Brief Summary

This study will assess the pharmacokinetics of RLX030 during and after administration in subjects with mild to severe hepatic impairment and matched healthy control subjects. 20 to 24 patients and 20...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • All subjects:
  • • Female subjects must be of non-child bearing potential OR use an effective method of contraception and sexually active males must use a condom during intercourse while taking the drug and for 5 half-lives after stopping treatment
  • Subjects with hepatic impairment:
  • Subjects must have either mild, moderate or severe hepatic impairment
  • Exclusion criteria:
  • All subjects
  • Hepatic impairment due to non-liver disease
  • Use of other investigational drugs at time of enrollment
  • History of malignancy of any organ system
  • Donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to initial dosing
  • Hemoglobin levels below 10.0 g/dL at screening or baseline
  • Subjects with hepatic impairment:
  • Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk
  • Treatment with any cytostatic drug, vasodilator, autonomic alpha blocker or B2 agonist
  • Any surgical or medical condition other than hepatic impairment which might significantly alter the distribution or excretion of drugs
  • Other protocol-defined inclusion/exclusion criteria may apply.

Exclusion

    Key Trial Info

    Start Date :

    July 1 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2011

    Estimated Enrollment :

    55 Patients enrolled

    Trial Details

    Trial ID

    NCT01433458

    Start Date

    July 1 2011

    End Date

    December 1 2011

    Last Update

    December 21 2020

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Novartis Investigative Site

    Grünstadt, Germany, D-67269

    2

    Novartis Investigative Site

    Moscow, Russia, 115419